Heterozygous Deficiency of Endoglin Decreases Insulin and Hepatic Triglyceride Levels during High Fat Diet

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Beiroa, Daniel ^a   Romero Picó, Amparo ^a   Langa, Carmen ^b   Bernabeu, Carmelo ^b   López, Miguel ^a   López Novoa, José M ^c   Nogueiras, Ruben ^a   Diéguez, Carlos ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^c INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA IBSAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOGLIN; GLUCOSE; GLUCOSE 6 PHOSPHATASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); PROTEIN KINASE B; TRIACYLGLYCEROL;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; ENERGY EXPENDITURE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HAPLOINSUFFICIENCY; HETEROZYGOSITY; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LIPID DIET; LIPID LIVER LEVEL; LOCOMOTION; MALE; MOUSE; NONHUMAN; OBESITY; RESPIRATORY QUOTIENT; SKELETAL MUSCLE;

ANIMALS; BODY WEIGHT; DIET, HIGH-FAT; ENERGY METABOLISM; GLUCOSE; HETEROZYGOTE; INSULIN; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER; MALE; MICE; MICE, KNOCKOUT; PHENOTYPE; SIGNAL TRANSDUCTION; TRIGLYCERIDES;

MUS;

EID: 84872421413     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054591     Document Type: Article

References (43)

1. Gougos A, Letarte M, (1990) Primary structure of endoglin, an RGD-containing glycoprotein of human endothelial cells. J Biol Chem 265: 8361-8364.
2. Lopez-Novoa JM, Bernabeu C, (2010) The physiological role of endoglin in the cardiovascular system. Am J Physiol Heart Circ Physiol 299: H959-974.
3. Cheifetz S, Bellon T, Cales C, Vera S, Bernabeu C, et al. (1992) Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem 267: 19027-19030.
4. Jerkic M, Rivas-Elena JV, Prieto M, Carron R, Sanz-Rodriguez F, et al. (2004) Endoglin regulates nitric oxide-dependent vasodilatation. FASEB J 18: 609-611.
5. Santibanez JF, Letamendia A, Perez-Barriocanal F, Silvestri C, Saura M, et al. (2007) Endoglin increases eNOS expression by modulating Smad2 protein levels and Smad2-dependent TGF-beta signaling. J Cell Physiol 210: 456-468.
6. Toporsian M, Gros R, Kabir MG, Vera S, Govindaraju K, et al. (2005) A role for endoglin in coupling eNOS activity and regulating vascular tone revealed in hereditary hemorrhagic telangiectasia. Circ Res 96: 684-692.
7. Jerkic M, Rivas-Elena JV, Santibanez JF, Prieto M, Rodriguez-Barbero A, et al. (2006) Endoglin regulates cyclooxygenase-2 expression and activity. Circ Res 99: 248-256.
8. Torsney E, Charlton R, Parums D, Collis M, Arthur HM, (2002) Inducible expression of human endoglin during inflammation and wound healing in vivo. Inflamm Res 51: 464-470.
9. Li C, Issa R, Kumar P, Hampson IN, Lopez-Novoa JM, et al. (2003) CD105 prevents apoptosis in hypoxic endothelial cells. J Cell Sci 116: 2677-2685.
10. Arthur HM, Ure J, Smith AJ, Renforth G, Wilson DI, et al. (2000) Endoglin, an ancillary TGFbeta receptor, is required for extraembryonic angiogenesis and plays a key role in heart development. Dev Biol 217: 42-53.
11. Bourdeau A, Dumont DJ, Letarte M, (1999) A murine model of hereditary hemorrhagic telangiectasia. J Clin Invest 104: 1343-1351.
12. Jerkic M, Rodriguez-Barbero A, Prieto M, Toporsian M, Pericacho M, et al. (2006) Reduced angiogenic responses in adult Endoglin heterozygous mice. Cardiovasc Res 69: 845-854.
13. Bernabeu C, Lopez-Novoa JM, Quintanilla M, (2009) The emerging role of TGF-beta superfamily coreceptors in cancer. Biochim Biophys Acta 1792: 954-973.
14. Perez-Gomez E, Del Castillo G, Juan Francisco S, Lopez-Novoa JM, Bernabeu C, et al. (2010) The role of the TGF-beta coreceptor endoglin in cancer. ScientificWorldJournal 10: 2367-2384.
15. ten Dijke P, Goumans MJ, Pardali E, (2008) Endoglin in angiogenesis and vascular diseases. Angiogenesis 11: 79-89.
16. Nassiri F, Cusimano MD, Scheithauer BW, Rotondo F, Fazio A, et al. (2011) Endoglin (CD105): a review of its role in angiogenesis and tumor diagnosis, progression and therapy. Anticancer Res 31: 2283-2290.
17. van Laake LW, van den Driesche S, Post S, Feijen A, Jansen MA, et al. (2006) Endoglin has a crucial role in blood cell-mediated vascular repair. Circulation 114: 2288-2297.
18. Parrish MR, Murphy SR, Rutland S, Wallace K, Wenzel K, et al. (2010) The effect of immune factors, tumor necrosis factor-alpha, and agonistic autoantibodies to the angiotensin II type I receptor on soluble fms-like tyrosine-1 and soluble endoglin production in response to hypertension during pregnancy. Am J Hypertens 23: 911-916.
19. Gilbert JS, Gilbert SA, Arany M, Granger JP, (2009) Hypertension produced by placental ischemia in pregnant rats is associated with increased soluble endoglin expression. Hypertension 53: 399-403.
20. McAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA, et al. (1994) Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 8: 345-351.
21. Shovlin CL, (2010) Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment. Blood Rev 24: 203-219.
22. Fernandez LA, Garrido-Martin EM, Sanz-Rodriguez F, Ramirez JR, Morales-Angulo C, et al. (2007) Therapeutic action of tranexamic acid in hereditary haemorrhagic telangiectasia (HHT): regulation of ALK-1/endoglin pathway in endothelial cells. Thromb Haemost 97: 254-262.
23. Blazquez-Medela AM, Garcia-Ortiz L, Gomez-Marcos MA, Recio-Rodriguez JI, Sanchez-Rodriguez A, et al. (2010) Increased plasma soluble endoglin levels as an indicator of cardiovascular alterations in hypertensive and diabetic patients. BMC Med 8: 86.
24. Fornoni A, Raij L, (2005) Metabolic syndrome and endothelial dysfunction. Curr Hypertens Rep 7: 88-95.
25. Hsueh WA, Lyon CJ, Quinones MJ, (2004) Insulin resistance and the endothelium. Am J Med 117: 109-117.
26. Rodriguez-Pena A, Eleno N, Duwell A, Arevalo M, Perez-Barriocanal F, et al. (2002) Endoglin upregulation during experimental renal interstitial fibrosis in mice. Hypertension 40: 713-720.
27. Czyzyk TA, Nogueiras R, Lockwood JF, McKinzie JH, Coskun T, et al. (2010) kappa-Opioid receptors control the metabolic response to a high-energy diet in mice. FASEB J 24: 1151-1159.
28. Nogueiras R, Perez-Tilve D, Veyrat-Durebex C, Morgan DA, Varela L, et al. (2009) Direct control of peripheral lipid deposition by CNS GLP-1 receptor signaling is mediated by the sympathetic nervous system and blunted in diet-induced obesity. J Neurosci 29: 5916-5925.
29. Gonzalez CR, Caminos JE, Vazquez MJ, Garces MF, Cepeda LA, et al. (2009) Regulation of visceral adipose tissue-derived serine protease inhibitor by nutritional status, metformin, gender and pituitary factors in rat white adipose tissue. J Physiol 587: 3741-3750.
30. Vazquez MJ, Gonzalez CR, Varela L, Lage R, Tovar S, et al. (2008) Central resistin regulates hypothalamic and peripheral lipid metabolism in a nutritional-dependent fashion. Endocrinology 149: 4534-4543.
31. Velasquez DA, Martinez G, Romero A, Vazquez MJ, Boit KD, et al. (2011) The central Sirtuin 1/p53 pathway is essential for the orexigenic action of ghrelin. Diabetes 60: 1177-1185.
32. Lee SJ, Kim JY, Nogueiras R, Linares JF, Perez-Tilve D, et al. (2010) PKCzeta-regulated inflammation in the nonhematopoietic compartment is critical for obesity-induced glucose intolerance. Cell Metab 12: 65-77.
33. Li DY, Sorensen LK, Brooke BS, Urness LD, Davis EC, et al. (1999) Defective angiogenesis in mice lacking endoglin. Science 284: 1534-1537.
34. Mahmoud M, Upton PD, Arthur HM, (2011) Angiogenesis regulation by TGFbeta signalling: clues from an inherited vascular disease. Biochem Soc Trans 39: 1659-1666.
35. Cudmore MJ, Ahmad S, Sissaoui S, Ramma W, Ma B, et al. (2012) Loss of Akt activity increases circulating soluble endoglin release in preeclampsia: identification of inter-dependency between Akt-1 and heme oxygenase-1. Eur Heart J 33: 1150-1158.
36. Arkan MC, Hevener AL, Greten FR, Maeda S, Li ZW, et al. (2005) IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med 11: 191-198.
37. Kahn BB, Flier JS, (2000) Obesity and insulin resistance. J Clin Invest 106: 473-481.
38. Pessin JE, Saltiel AR, (2000) Signaling pathways in insulin action: molecular targets of insulin resistance. J Clin Invest 106: 165-169.
39. Graham TE, Kahn BB, (2007) Tissue-specific alterations of glucose transport and molecular mechanisms of intertissue communication in obesity and type 2 diabetes. Horm Metab Res 39: 717-721.
40. Carobbio S, Rodriguez-Cuenca S, Vidal-Puig A, (2011) Origins of metabolic complications in obesity: ectopic fat accumulation. The importance of the qualitative aspect of lipotoxicity. Curr Opin Clin Nutr Metab Care 14: 520-526.
41. Wu Q, Ortegon AM, Tsang B, Doege H, Feingold KR, et al. (2006) FATP1 is an insulin-sensitive fatty acid transporter involved in diet-induced obesity. Mol Cell Biol 26: 3455-3467.
42. Casimir M, Lasorsa FM, Rubi B, Caille D, Palmieri F, et al. (2009) Mitochondrial glutamate carrier GC1 as a newly identified player in the control of glucose-stimulated insulin secretion. J Biol Chem 284: 25004-25014.
43. Nishi Y, Fujimoto S, Sasaki M, Mukai E, Sato H, et al. (2011) Role of mitochondrial phosphate carrier in metabolism-secretion coupling in rat insulinoma cell line INS-1. Biochem J 435: 421-430.